PDL BioPharma, Inc. (NASDAQ: PDLI) is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of leading products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL’s research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit www.pdl.com.
TODAY’S HEADLINES: BrainCells raises $30M for neuroregeneration drugs (release) EKR Therapeutics takes in $50M plus $95M in debt for pain,… Continue reading 〉
A few months ago, I wrote about the intriguing trend toward “re-launching” biotech startups that had been recently acquired by… Continue reading 〉